Agenus (NASDAQ:AGEN) Sets New 1-Year Low at $8.10

Shares of Agenus Inc. (NASDAQ:AGEN) reached a new 52-week low on Friday . The company traded as low as $8.10 and last traded at $8.16, with a volume of 93931 shares. The stock had previously closed at $8.87.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AGEN shares. B. Riley decreased their target price on Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Agenus in a report on Thursday, March 14th. Finally, StockNews.com raised Agenus from a “sell” rating to a “hold” rating in a report on Sunday, March 24th.

Agenus Stock Performance

The business has a fifty day simple moving average of $12.49 and a 200 day simple moving average of $14.70. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -11.48 and a beta of 1.26.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The business had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. On average, sell-side analysts forecast that Agenus Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Garo H. Armen bought 25,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was purchased at an average cost of $13.00 per share, for a total transaction of $325,000.00. Following the transaction, the insider now owns 31,298 shares in the company, valued at approximately $406,874. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Agenus

A number of institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. lifted its position in shares of Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 2,232,064 shares during the last quarter. Swiss National Bank lifted its position in shares of Agenus by 5.9% during the 3rd quarter. Swiss National Bank now owns 690,100 shares of the biotechnology company’s stock worth $780,000 after buying an additional 38,600 shares during the last quarter. Citigroup Inc. lifted its position in shares of Agenus by 41.0% during the 3rd quarter. Citigroup Inc. now owns 707,213 shares of the biotechnology company’s stock worth $799,000 after buying an additional 205,817 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Agenus by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after buying an additional 27,137 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Agenus by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 107,291 shares of the biotechnology company’s stock worth $121,000 after buying an additional 15,370 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.